Pharma major Lupin today launched an anti-depression generic drug Pristiq in the US.
"We have received approval from the US Food and Drug Administration to launch generic drug Pristiq for treating major depressive disorder. This extended-release tablet is the AB-rated generic equivalent of Wyeth Pharmaceuticals' Pristiq tablets," Lupin said in a statement.
Pristiq tablets had annual sales of around USD 860 million in the US.
Lupin is a major player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and holds global leadership position in the anti-TB segment and develops and sells a range of branded and generic formulations, biotechnology products and APIs globally.
Disclaimer: No Business Standard Journalist was involved in creation of this content
